Nicole Negar Davarpanah - 01 May 2025 Form 3 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role: Chief Medical Officer
Signature: /s/ Shane Ward, Attorney-in-Fact
Issuer symbol: CDTX
Transactions as of: 01 May 2025
Net transactions value: $0
Form type: 3
Filing time: 12 May 2025, 20:37:41 UTC
Next filing: 15 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Davarpanah Nicole Negar	Chief Medical Officer	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO	/s/ Shane Ward, Attorney-in-Fact	12 May 2025	0002067554

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CDTX	Common Stock						21,692	01 May 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CDTX	Employee Stock Option (right to buy)							01 May 2025	Common Stock	11,000	$18.84	Direct	F1
holding	CDTX	Employee Stock Option (right to buy)							01 May 2025	Common Stock	5,000	$13.70	Direct	F2
holding	CDTX	Employee Stock Option (right to buy)							01 May 2025	Common Stock	62,597	$10.75	Direct	F3
holding	CDTX	Employee Stock Option (right to buy)							01 May 2025	Common Stock	30,000	$21.54	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares subject to the option shall vest and become exercisable on the 1st anniversary of the Vesting Commencement Date of August 16, 2023, and the balance of the shares shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the 1st anniversary of the Vesting Commencement Date, subject to continuous service through each such Vesting Date.
F2	The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 15, 2024, subject to continuous service through each such Vesting Date.
F3	The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of September 30, 2024, subject to continuous service through each such Vesting Date.
F4	The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2025, subject to continuous service through each such Vesting Date.